Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

324813 Soluble Epoxide Hydrolase Inhibitor, NCND - CAS 402939-18-8 - Calbiochem

324813
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
324813-25MG Plastic ampoule 25 mg
Description
OverviewA cell-permeable 1,3-disubstituted urea compound that displays anti-hypertensive and anti-inflammatory properties. Acts as a potent, selective, competitive, and tight-binding transition-state analog inhibitor of soluble epoxide hydrolase (sEH; IC50 = 9.8 nM for mouse recombinant sEH, 85.2 nM for human recombinant sEH). Reported to decrease human VSMC (vascular smooth muscle cell) proliferation.
Catalogue Number324813
Brand Family Calbiochem®
SynonymsCDU, N-Cyclohexyl-Nʹ-dodecylurea, 1-Cyclohexyl-3ʹ-dodecylurea
References
ReferencesNewman, J.W., et al. 2003. Proc. Natl. Acad. Sci. USA 100, 1558.
Davis, B.B., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 2222.
Morisseau, C., et al. 2002. Biochem. Pharmacol. 63, 1599.
Imig, J.D., et al. 2002. Hypertension 39, 690.
Argiriadi, M.A., et al. 2000. J. Biol. Chem. 275, 15265.
Yu, Z., et al. 2000. Circ. Res. 87, 992.
Product Information
CAS number402939-18-8
ATP CompetitiveY
FormWhite solid
Hill FormulaC₁₉H₃₈N₂O
Chemical formulaC₁₉H₃₈N₂O
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetSoluble epoxide hydrolase
Primary Target IC<sub>50</sub>9.8 nM for mouse recombinant sEH, 85.2 nM for human recombinant sEH
Purity≥95% by TLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
324813-25MG 04055977216172

Documentation

Soluble Epoxide Hydrolase Inhibitor, NCND - CAS 402939-18-8 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

Soluble Epoxide Hydrolase Inhibitor, NCND - CAS 402939-18-8 - Calbiochem Certificates of Analysis

TitleLot Number
324813

References

Reference overview
Newman, J.W., et al. 2003. Proc. Natl. Acad. Sci. USA 100, 1558.
Davis, B.B., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 2222.
Morisseau, C., et al. 2002. Biochem. Pharmacol. 63, 1599.
Imig, J.D., et al. 2002. Hypertension 39, 690.
Argiriadi, M.A., et al. 2000. J. Biol. Chem. 275, 15265.
Yu, Z., et al. 2000. Circ. Res. 87, 992.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision08-April-2011 RFH
SynonymsCDU, N-Cyclohexyl-Nʹ-dodecylurea, 1-Cyclohexyl-3ʹ-dodecylurea
DescriptionA cell-permeable, potent, selective, competitive, and tight binding transition-state analog inhibitor of soluble epoxide hydrolase (sEH) (IC50 = 9.8 nM for recombinant murine sEH and 85.2 nM for recombinant human sEH). Also displays anti-hypertensive and anti-inflammatory properties. Reported to decrease human vascular smmoth muscle cell (VSMC) proliferation.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number402939-18-8
Chemical formulaC₁₉H₃₈N₂O
Structure formulaStructure formula
Purity≥95% by TLC
SolubilityCH₂Cl₂ (1 mg/ml)
Storage +2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesNewman, J.W., et al. 2003. Proc. Natl. Acad. Sci. USA 100, 1558.
Davis, B.B., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 2222.
Morisseau, C., et al. 2002. Biochem. Pharmacol. 63, 1599.
Imig, J.D., et al. 2002. Hypertension 39, 690.
Argiriadi, M.A., et al. 2000. J. Biol. Chem. 275, 15265.
Yu, Z., et al. 2000. Circ. Res. 87, 992.